Apogee Therapeutics Overview
- Year Founded
-
2022
- Status
-
Acquired/Merged
- Employees
-
261
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$10.1B
Apogee Therapeutics General Information
Description
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Contact Information
Website
www.apogeetherapeutics.com(Operating Subsidiary)
Corporate Office
- 221 Crescent Street
- Waltham, MA 02453
- United States
Corporate Office
- 221 Crescent Street
- Waltham, MA 02453
- United States
Apogee Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 03-Sep-2026 | $10.1B | Completed | Generating Revenue | ||
| 8. General Corporate Purpose | 27-May-2026 | Completed | Generating Revenue | |||
| 7. 2PO | 24-Mar-2026 | Completed | Generating Revenue | |||
| 6. 2PO | 10-Oct-2025 | Completed | Generating Revenue | |||
| 5. 2PO | 11-Mar-2024 | Completed | Generating Revenue | |||
| 4. IPO | 13-Jul-2023 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 07-Dec-2022 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 01-Jun-2022 | $20M | $20M | Completed | Pre-Clinical Trials | |
| 1. Spin-Off | 01-Jan-2022 | Completed | Pre-Clinical Trials |
Apogee Therapeutics Comparisons
Industry
Financing
Details
Apogee Therapeutics Competitors (66)
One of Apogee Therapeutics’s 66 competitors is Sorrento Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Adiso Therapeutics | Venture Capital-Backed | Newton, MA | ||||
| Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Apogee Therapeutics Patents
Apogee Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213500-A1 | Dosage and administration of ox40l antibodies in combination with il-13 antibodies | Pending | 04-Apr-2025 | ||
| WO-2026151705-A1 | Dosage and administration of interleukin-13 antibody to treat asthma | Pending | 07-Jan-2025 | ||
| WO-2026151705-A9 | Dosage and administration of interleukin-13 antibody to treat asthma | Pending | 07-Jan-2025 | ||
| WO-2026112477-A1 | Co-formulation of ox40l antibodies and il-13 antibodies | Pending | 22-Nov-2024 | ||
| WO-2026112418-A2 | Ox40l antibody formulation | Pending | 22-Nov-2024 | A61K39/39591 |
Apogee Therapeutics Signals
Apogee Therapeutics Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| Fairmount Partners | Investment Bank | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| OrbiMed | Growth/Expansion | Minority |
Apogee Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Apogee Therapeutics FAQs
-
When was Apogee Therapeutics founded?
Apogee Therapeutics was founded in 2022.
-
Where is Apogee Therapeutics headquartered?
Apogee Therapeutics is headquartered in Waltham, MA.
-
What is the size of Apogee Therapeutics?
Apogee Therapeutics has 261 total employees.
-
What industry is Apogee Therapeutics in?
Apogee Therapeutics’s primary industry is Biotechnology.
-
Is Apogee Therapeutics a private or public company?
Apogee Therapeutics is a Private company.
-
What is the current valuation of Apogee Therapeutics?
The current valuation of Apogee Therapeutics is .
-
What is Apogee Therapeutics’s current revenue?
The current revenue for Apogee Therapeutics is .
-
How much funding has Apogee Therapeutics raised over time?
Apogee Therapeutics has raised $2.12B.
-
Who are Apogee Therapeutics’s investors?
Access Biotechnology, Deep Track Capital, Fairmount Partners, Fidelity Management & Research Company, and OrbiMed are 5 of 12 investors who have invested in Apogee Therapeutics.
-
Who are Apogee Therapeutics’s competitors?
Sorrento Therapeutics, Adiso Therapeutics, Innovimmune Biotherapeutics, Minerva Neurosciences, and Sarepta Therapeutics are some of the 66 competitors of Apogee Therapeutics.
-
When was Apogee Therapeutics acquired?
Apogee Therapeutics was acquired on 03-Sep-2026.
-
Who acquired Apogee Therapeutics?
Apogee Therapeutics was acquired by AbbVie.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process